oesophageal cancer
Oncology · 2009–2023
8decisions
3medicines
5carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| nivolumab First-line treatment of advanced or metastatic oesophageal squamous cell carcinoma (OSCC) in patients with tumour cell PD-L1 expression ≥1%, either in… | Mar 2023 | Recommended | unclear |
| nivolumab Adjuvant treatment of stage II or III oesophageal carcinoma (OC) or gastro-oesophageal junction carcinoma (GOJC) who have received platinum-based… | Jul 2022 | Not recommended | 1 individuals Medical Oncology Group |
| pembrolizumab In combination with platinum- and fluoropyrimidine-based chemotherapy for first-line treatment of patients with locally advanced (Stage III) or metastatic… | May 2022 | Recommended | input received |
| pembrolizumab Treatment of locally advanced (Stage III) or metastatic (Stage IV) oesophageal adenocarcinoma (OAC) or oesophageal squamous cell carcinoma (OSCC), or… | Mar 2022 | Not recommended | input received |
| nivolumab Adjuvant treatment of stage II or III oesophageal cancer or gastro-oesophageal junction cancer in patients who have received neoadjuvant platinum-based… | Nov 2022 | Recommended with restriction | input received Medical Oncology Group |
| pembrolizumab Locally advanced (Stage III) or metastatic (Stage IV) oesophageal adenocarcinoma, oesophageal squamous cell carcinoma, or HER2-negative adenocarcinoma of the… | Nov 2021 | Not recommended | input received |
| capecitabine Treatment of previously untreated advanced oesophago-gastric cancer in combination with a cisplatin-based regimen in patients with WHO performance status of 2… | Mar 2010 | Recommended with restriction | no section in document |
| capecitabine Treatment, in combination with a platinum-based regimen, of a patient with previously untreated advanced oesophago-gastric cancer with a WHO performance status… | Jul 2009 | Recommended | no section in document |
Who spoke
Medical Oncology Group
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 5 of 6 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.